#4D PHARMA ONCOLOGY TRIAL#

Publication - The fecal mycobiome in patients with Irritable Bowel Syndrome, Scientific Reports Engineering live biotherapeutics: approaches, challenges and applications Keystone Symposia, Synthetic Biology: At the Crossroads of Genetic Engineering and Human Therapeutics.

#4D PHARMA ONCOLOGY TRIAL#

Publication - Microbial short-chain fatty acids modulate CD8+ T cell responses and improve adoptive immunotherapy for cancer, Nature CommunicationsĭDW 2021 Virtual R&D Event: Phase II clinical trial of Blautix as a treatment for IBS-C and IBS-DĭDW 2021 - A Phase II randomized, multi-center study to evaluate the efficacy and safety of the oral single strain Live Biotherapeutic Product (LBP) Blautix in subjects with IBS-C and IBS-D Gastro 2021 - Administration of a Live Biotherapeutic is associated with Microbiome Structural Changes and the Alleviation of IBS symptomology: Results from Blautix® Phase II RCTĮSMO 2021 - Baseline biomarkers associated with clinical benefit in patients with solid tumours refractory to immune checkpoint inhibitors (ICIs) treated with live biotherapeutic MRx0518 in combination with pembrolizumabĮSMO 2021 - Neoadjuvant MRx0518 treatment is associated with significant gene and metagene signature changes in solid tumours Keystone Symposia: Neurodegeneration - Harnessing the Neuromodulatory Effects of Live Biotherapeutic Products (LBPs) Derived from the Gut Microbiota to Treat Parkinson’s DiseaseĪSCO 2022 - Trial in progress: A Phase II switch maintenance study of live biotherapeutic MRx0518 and avelumab in patients with unresectable locally advanced or metastatic urothelial carcinoma (UC) who did not progress on first-line platinum-containing chĪTS 2022 - Safety, Tolerability and Preliminary Signals of Activity in Adult Patients with Partly Controlled Asthma Treated with Live Biotherapeutic MRx-4DP0004 as an Add-On Maintenance Therapy to Inhaled Corticosteroids (ICS) With or Without Long-Acting

SITC 2022 - Oral administration of MRx0518 in treatment-naïve cancer patients is associated with compositional taxonomic and metabolomic changes indicative of anti-tumorigenic efficacy

SITC 2022 - Combination of MRx0518 and anti-PD-1 overcomes checkpoint inhibitor resistance via myeloid modulation

4d pharma oncology